Two immune drugs, with or without targeted brain radiation, for melanoma that spread to the brain
Original title: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the treatment is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial asks if adding targeted brain radiation to two immune drugs works better than the drugs alone.
Who this trial is for. This trial is for people whose melanoma has spread to the brain. The brain spots have not been treated and are not causing symptoms. People are put into two groups by chance. One group gets the drugs ipilimumab and nivolumab plus targeted radiation to the brain. The other group gets those two drugs alone.
Where it stands. This trial has not reported results. It is comparing the two drugs with radiation against the two drugs alone. The answer is not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a question being studied, not a known answer. If this sounds like your situation, you could ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean the added radiation is proven to help. A trial is a test, not care that is known to work. Joining one is not a guarantee that you will do better. It is also not a promise of a cure.
Source: ClinicalTrials.gov, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.